5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.
Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of growth in 2014, payer restrictions and the fact that Gilead had cured most of the sickest patients left management searching for new ways to create shareholder value by 2016.
Gilead has a lot of money to do just that: $34.6 billion in cash and short- and long-term investments. Here are a few ways it could use that cash hoard.
Source: Fool.com
Gilead Sciences Inc Stock
€60.78
2.870%
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 84 € shows a positive potential of 38.2% compared to the current price of 60.78 € for Gilead Sciences Inc.
